what do glp 1 inhibitors do Glucagon-like peptide-1 Glucagon-Like Peptide-1: New Regulator in

Theyll utilize real-world electronic health records, machine learning, and other novel methods to investigate changes in obesity-related healthcare usage before and after the emergence of these medications, as well as identify predictors of GLP-1-assisted weight loss, the drugs effectiveness by subpopulation, and how these rapidly evolving therapies may influence future life expectancy based on policy changes that address the existing disparities in access and use.

12 mg), 7.2 kg (15.8 lbs

Adults interested in recovery support, healthy aging, wellness optimization, or body composition goals may qualify for evaluation

Epub 2004 Nov 30.10.1159/000082456 [PubMed: 15583470] [CrossRef] 58